<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.</title>
    <meta name="description" content="Caution – CE marked since 2019.; FDA approved in August 2025 as prescription-only device.; Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021." />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.</h1>
<div class="muted">2025-09-15 20:10:00+00:00</div>
<hr />
<div class="list"><ul>
  <li>Caution – CE marked since 2019.</li><li>FDA approved in August 2025 as prescription-only device.</li><li>Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021.</li><li>Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019.</li><li>Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc.</li><li>8,700,183, 9,415,215, and 9,415,216.</li><li>Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/nyxoah-files-patent-infringement-lawsuit-201000143.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Nyxoah+Files+Patent+Infringement+Lawsuit+Against+Inspire+Medical+Systems%2C+Inc.%0A%E2%80%A2+Caution+%E2%80%93+CE+marked+since+2019.%0A%E2%80%A2+FDA+approved+in+August+2025+as+prescription-only+device.%0A%E2%80%A2+Nyxoah+completed+two+successful+IPOs%3A+on+Euronext+Brussels+in+September+2020+and%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fnyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-inc%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>